Nu-Med Plus (NUMD) Equity Ratio (2011 - 2025)

Nu-Med Plus has disclosed Equity Ratio across 15 years of filings, most recently posting 34.29 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 34.29, down 49.43% year-over-year; the trailing twelve-month figure through Dec 2025 was 34.29 (down 49.43% YoY), and the FY2025 annual result was 34.29, down 49.43% from the prior year.
• Equity Ratio came in at 34.29 for Q4 2025 at Nu-Med Plus, up from 51.24 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.67 in Q1 2021 to a low of 85.27 in Q3 2022.
• The 5-year median for Equity Ratio is 17.77 (2024), against an average of 21.03.
• Across the five-year window, Equity Ratio jumped 108.61% in 2021 and sank 157942.44% in 2022, its largest moves.
• Nu-Med Plus' Equity Ratio stood at 5.97 in 2021, then surged by 86.73% to 0.79 in 2022, then plunged by 1276.46% to 10.91 in 2023, then slumped by 110.42% to 22.95 in 2024, then plunged by 49.43% to 34.29 in 2025.
• The last three Equity Ratio figures came in at 34.29 (Q4 2025), 51.24 (Q3 2025), and 30.22 (Q2 2025), per Business Quant data.